Related Experiment Video
Updated: Oct 23, 2025

In vitro Neuromuscular Junction Induced from Human Induced Pluripotent Stem Cells
Published on: December 3, 2020
Current status and future directions of clinical applications using iPS cells-focus on Japan
Hiraku Tsujimoto1,2, Kenji Osafune1,3
1Center for iPS Cell Research and Application (CiRA), Kyoto University, Japan.
Abstract:
Regenerative medicine using iPS cell technologies has progressed remarkably in recent years. In this review, we summarize these technologies and their clinical application. First, we discuss progress in the establishment of iPS cells, including the HLA-homo iPS cell stock project in Japan and the advancement of low antigenic iPS cells using genome-editing technology. Then, we describe iPS cell-based therapies in or approaching clinical application, including those for ophthalmological, neurological, cardiac, hematological, cartilage, and metabolic diseases. Next, we introduce disease models generated from patient iPS cells and successfully used to identify therapeutic agents for intractable diseases. Clinical medicine using iPS cells has advanced safely and effectively by making full use of current scientific standards, but tests on cell safety need to be further developed and validated. The next decades will see the further spread of iPS cell technology-based regenerative medicine.
Related Concept Videos
EPS and iPS Cells in Disease Research
iPS Cell Differentiation
Induced Pluripotent Stem Cells
Somatic...
Induced Pluripotent Stem Cells
Somatic to iPS Cell Reprogramming
Clinical Applications of Epidermal Stem Cells

